CP and chronic kidney disease: We also perfused NASPM (200 μM), a selective antagonist for CP-AMPARs39, but we failed to detect any difference in NASPM sensitivity between the cKD and control groups, regardless of cocaine treatment (Fig. 3b and Supplementary Fig. 4d).